Skip to content
thestock.space

As of 6 Nov 2026, Neuland Laboratories trades at 55.9× trailing earnings, above the industry P/E of 28.7×, and the shares are 19% below their 52-week high. Its ROCE of 23% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 19% and 31% a year over 3 years. Its dividend yield is 0.2%, and debt is 0.17× equity. It is a small-cap company with a market cap of ₹25,275 Cr, ranked 20th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 12% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹19,500.00
Day high
₹19,750.00
Day low
₹19,205.00
Prev. close
₹19,783.00
Volume
61.3K

Health check

3 good · 3 to check
  • ReturnsBehind

    +12.4% over a year, better than 2 of 7 peers.

  • Price tagPricier

    P/E 55.9 vs industry 28.7.

  • GrowthStrong

    Sales +18.5%, profit +30.6% a year over 3 years.

  • ProfitabilityStrong

    ROCE 22.9% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.17× equity, interest covered 27.2×, Piotroski 6 of 9.

  • Red flags3 to check

    Quarterly profit down 46.7% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹25,275 Cr, #20 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹2,314 Cr · profit ₹453 Cr
Market cap
₹25,275 Cr
Small cap
P/E
55.9
Industry 28.7
Price to book
12.45
Peers 4.99
Dividend yield
0.17%
ROE
24.8%
Peers 14.7%
ROCE
22.9%
Peers 17.9%
Debt to equity
0.17
Debt ₹342 Cr
EPS (TTM)
₹352.73
Face value ₹10
OPM (TTM)
30.6%
Net margin 19.6%
Sales growth
−12.6%
Latest quarter vs a year ago
Profit growth
−46.7%
Latest quarter vs a year ago
Price to sales
10.92
EV/EBITDA 35.7

Strengths and risks

Strengths

  • Return on equity of 24.8%.
  • Return on capital employed of 22.9%.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Quarterly profit down 46.7% on a year ago.
  • Quarterly sales down 12.6% on a year ago.
  • P/E of 55.9 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Neuland Laboratories

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland…

Headquarters
Hyderabad
Employees
2,183
Sector
Healthcare
ISIN
INE794A01010
Website
neulandlabs.com

Price range

52 weeks

₹11,500.00₹24,225.00

Today

₹19,205.00₹19,750.00
Avg volume (3M)
51.3K
1-year return
plus 12.4%
From 52-week high
minus 18.7%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
NEULANDLABNeuland Laboratories19,700.00minus 0.42%25,27555.912.4522.9%24.8%30.6%18.5%30.6%0.17%plus 12.4%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
514440776642450
359363469419352
15677.130722397.6
30.2%17.5%39.6%34.7%21.7%
1.88.112.58.57.5
5.46.87.277.3
22.523.925.126.628.8
12954.528719869
25.2%25.5%26.0%25.4%25.2%
96.940.621314851.6
75.4931.62165.76115.1040.24

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+18.5%
Profit CAGR 3Y
+30.6%
EPS CAGR 3Y
+30.6%
ROE
24.8%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1,1611,5161,4341,932
–+30.6%minus 5.4%+34.7%
8741,0491,1021,350
287467332582
24.7%30.8%23.2%30.1%
−10.95.28.715.4
10.411.15.818.7
52.859.765.591.7
2.7−0.176.92.3
216401346489
24.2%25.2%24.9%25.6%
164300260364
–+83.5%minus 13.3%+39.9%
127.45233.89202.74283.71

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
12.912.912.912.9
9811,2701,5121,862
12895.4157301
457454498754
1,5801,8332,1802,930
5005907331,143
42.467.159.7251
0.51.31.52
45.4103352327
9921,0721,0331,208
1,5801,8332,1802,930

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
237261317347
−61.5−150−298−424
−136−69.32521
39.942.244.2−56.1
−66.1−144−206−397
171118111−50.5
−6.4−12.8−18−15.4

Shareholding pattern

Source: NSE filings
32.3%
promoters
  • Promoters32.26%
  • Public67.74%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202632.26%67.74%minus 0.36
30 Jun 202632.62%67.38%minus 0.01
31 Mar 202632.63%67.37%0.00
31 Dec 202532.63%67.37%minus 0.01
30 Sep 202532.64%67.36%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you